Cubist Systematic Strategies’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cubist Systematic Strategies’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-27,452	Closed	-$75K	–	3266
2021 Q2	$75K	Sell	27,452 -80,798	-75%	-$201K	﹤0.01%	2751
2021 Q1	$283K	Buy	+108,250	New	+$306K	﹤0.01%	2292
2019 Q2	–	Sell	-13,613	Closed	-$145K	–	2636
2019 Q1	$145K	Buy	+13,613	New	+$136K	﹤0.01%	1912
2018 Q3	–	Sell	-4,049	Closed	-$73K	–	2150
2018 Q2	$73K	Sell	4,049 -1,644	-29%	-$24.2K	﹤0.01%	1601
2018 Q1	$61K	Buy	5,693 +385	+7%	+$6.18K	﹤0.01%	1667
2017 Q4	$224K	Buy	5,308 +3,188	+150%	+$143K	0.01%	1456
2017 Q3	$117K	Buy	+2,120	New	+$358K	0.01%	1597
2017 Q2	–	Sell	-42	Closed	-$5K	–	1931
2017 Q1	$5K	Sell	42 -46	-52%	-$4.82K	﹤0.01%	1582
2016 Q4	$9K	Sell	88 -1,138	-93%	-$120K	﹤0.01%	1655
2016 Q3	$137K	Buy	+1,226	New	+$147K	0.01%	1397
2015 Q4	–	Sell	-68	Closed	-$7K	–	2010
2015 Q3	$7K	Buy	+68	New	+$7.97K	﹤0.01%	1815

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cubist Systematic Strategies's SIOX Position: Q3 2021 in Review

Cubist Systematic Strategies sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2021, closing a stake of 27,452 shares — an estimated $75K sold.

Cubist Systematic Strategies first reported a position in SIOX in Q3 2015 and held it in 11 quarters. The position peaked at $283K in Q1 2021. 56 funds tracked by Wall St. Rank hold SIOX as of Q3 2021.

Cubist Systematic Strategies reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Cubist Systematic Strategies sold 27,452 Sio Gene Therapies Inc. Common Stock shares in Q3 2021, an estimated $75K.
Cubist Systematic Strategies first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 11 quarters.
Cubist Systematic Strategies's Sio Gene Therapies Inc. Common Stock position peaked at $283K in Q1 2021.
56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2021.

Based on Cubist Systematic Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.